DEVELOPING
MAJOR78
CLINICAL TRIALLimited grounding
Amgen launches late-stage obesity trial in patients who switch from rival drugs
Amgen is testing its obesity drug MariTide in a new late-stage trial that includes patients switching from rival weight-loss drugs made by Eli Lilly and Novo Nordisk. The company is also launching two other large trials to gather more evidence that MariTide works.
Analysis
Amgen's switch-trial design directly targets Lilly and Novo patients, signaling MariTide is being positioned as a second-line option rather than first-line challenger.
- Amgen launched a late-stage MariTide trial including patients switching from Lilly and Novo drugs
- Two additional large MariTide trials are also being launched
- Trials aim to gather more evidence that MariTide works
Endpoints News2d
Read